Cell Therapy Manufacturing Market Set to Witness Adamant Growth through 2018-2026 Predicted by Global Top Players

Cell
therapy is
one of the most promising healthcare procedure for restoration of
damaged tissue. Cell therapies have huge potential for the wide range
of disease treatment including tissue degradation, immune deficiency,
metabolic disorders, and cancer. Cell therapy are categorized into
two type’s allogeneic (cells from third party donor) and autologous
(cells from one’s own body). Cell therapy has gained significant
traction in recent past and currently it under commercial
development. Main objective of cell therapy is to re-establish the
lost function of tissues and cells rather than to produce a new
organ. Some cell therapies have been established and permitted for
clinical trial. For instance, in 2013 a stage 2 clinical trial was
completed for transplantation of bone marrow derived stem cells in
affected knee by rheumatoid arthritis. The growth of this technique
is also increased due to involvement of the government agencies. For
instance, innovate U.K. 2014 report showed that government agreed to
fund US$15.3 million in cell therapy manufacturing market.
Cell
Therapy Manufacturing Market Dynamics
Increasing
number of surgical procedures performed across the world coupled with
increasing number of trauma and accidents is propelling demand for
new medical therapy. For instance, according to a 2015, World Health
Organization (WHO) report, more than 50,000 stem cell transplants are
carried out annually worldwide for various surgeries. Stem cells
transplantation is promising medical therapy for patients with
advance stage diseases like Alzheimer’s, arthritis, autism,
blindness, cancer, cerebral palsy, diabetes etc. Key
biopharmaceutical companies are majorly investing in research for
cell therapy. For instance, Longeveron LL, a biopharmaceutical
company received a US$ 750,000 grant from the Maryland Technology
Development Corporation (TEDCO) in 2018 for stem cell therapy
research. These collaborations and government funding are boosting
growth of the cell therapy manufacturing market. However, the strict
regulations, guidelines, and various health safety concerns over cell
therapy treatment are restraining growth of the cell therapy market.
Cell
Therapy Manufacturing Market - Regional Insights
On
the basis of the region, the global cell therapy market is segmented
into North America, Latin America, Europe, Asia Pacific, Middle East,
and Africa. North America holds the dominant position in the global
cell therapy manufacturing market, owing to large number of surgeries
performed in the region as well as development of technologically
advanced products for therapy. According to the National Health
Statistics Report by the Centers for Disease Control & Prevention
(CDC), around 201,748.3 million surgical and non-surgical procedures
were performed in the U.S. in 2011.
Furthermore,
Asia Pacific is projected to witness significant growth in the global
cell therapy manufacturing market in the near future. Marginal market
share would be grabbed by the local players entering into market due
to less stringent regulatory requirements and growing customer pool
prone to various chronic and infectious disease such as cancer, HIV,
hepatitis etc. Therefore induction of cell therapy can provide better
solutions to the patient at the marginally lower cost.
Inquire
Here Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1728
Cell
Therapy Manufacturing Market - Competitive Insights
The key player operating in
the global cell therapy manufacturing market include, Pharmicell,
Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group,
Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies,
Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad
Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate,
Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy
Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and
WuXi AppTec. Key players are adoption growth strategies such as
collaborations, introduction of new technologies and devices to
maintain dominant position in the market. For instance, in 2014,
ViaCyte, Inc. successfully implanted VC-01 an embryonic stem cell
derived islet for the treatment of type 1 diabetes.
Cell
Therapy Manufacturing Market Taxonomy
On
the basis of therapy type, the global cell therapy manufacturing
market is segmented into:
Allogeneic
Cell Therapy
Autologous
Cell Therapy
On
the basis of technology, the global cell therapy manufacturing market
is segmented into:
Somatic
Cell Technology
Cell
Immortalization Technology
Viral
Vector Technology
Genome
Editing Technology
Cell
Plasticity Technology
3D
Technology
On
the basis of source, the global cell therapy manufacturing market is
segmented into:
IPSC’s
(Induced pluripotent stem cell)
Bone
marrow
Umbilical
cord
Adipose
tissue
Neural
stem
On
the basis of application, the global cell therapy manufacturing
market is segmented into:
Musculoskeletal
Cardiovascular
Gastrointestinal
Neurological
Oncology
Dermatology
Others
On
the basis of region, the global cell therapy manufacturing market is
segmented into:
North
America
Latin
America
Europe
Asia
Pacific
Middle
East
Africa
About
Coherent Market Insights
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us
Mr.
Shah
Coherent
Market Insights
1001
4th Ave, #3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
Comments
Post a Comment